By Ashley Turner, PhD, Scientist, Regulatory Strategy
In 2020, CDER approved 68 NDAs that used the 505(b)(2) pathway, representing important advances in patient care across a wide range of therapeutic areas.
Not yet a member of Clinical Leader? Register today.
Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.
You might also want to: